Portal de Periódicos da CAPES

Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study

2019; Lippincott Williams & Wilkins; Volume: 37; Issue: 16 Linguagem: Inglês

10.1200/jco.18.01568

1527-7755

Joan L. Walker, Mark F. Brady, Lari Wenzel, Gini F. Fleming, Helen Q. Huang, Paul DiSilvestro, Keiichi Fujiwara, David S. Alberts, Wenxin Zheng, Krishnansu S. Tewari, David E. Cohn, Matthew A. Powell, Linda Van Le, Susan A. Davidson, Heidi J. Gray, Peter G. Rose, Carol Aghajanian, Tashanna Myers, Angeles Alvarez Secord, Stephen C. Rubin, Robert S. Mannel,

Testicular diseases and treatments

To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma.